Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Zora Biosciences commercializes VTT's biotechnology expertise

21.06.2007
VTT Technical Research Center of Finland has spun-off Zora Biosciences Oy, the only company in the Nordic countries to offer metabolomics services to drug developers. Zora also develops biomarkers, which, for example, make it possible to detect early signs of cardiovascular disease.

VTT Technical Research Center of Finland has launched a spin-off company, Zora Biosciences Oy. "Zora's speciality field of metabolomics is a major driver of biomedical and pharmaceutical research", says Matej Orešic, founder and chairman of the board.

Zora's business model is two-fold. Zora will provide sophisticated laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics. Also, based on this advanced laboratory expertise Zora will develop prognostic and diagnostic biomarkers for human diseases as well as drug safety and efficacy monitoring.

Zora will aggressively expand its biomarker portfolio for licensing the discoveries to laboratory assay providers. At present, Zora's biomarker portfolio includes a promising discovery for screening patients susceptible to side effects of statins, which are powerful cholesterol lowering drugs. Statin medication is used by millions world-wide as part of their treatment regimen for cardiovascular diseases. Zora is also developing prognostic and diagnostics tools for improved healthcare management of diabetes and coronary artery disease among other indication areas.

... more about:
»Biomarker »Biosciences »metabolomics

Zora is funded by VTT, Slovenian private investor Gomar D.D., and Seedcap II Ky, managed by Innofinance Oy. "Zora has strong potential for rapid business growth and internationalization, which has attracted a committed investor base for the company", says Reini Hurme, Zora CEO. Globally there is only a handful of companies specializing in metabolomics, in the Nordic countries Zora is the only one.

Zora Biosciences Oy

Zora Biosciences offers advanced laboratory services for the needs of the pharmaceutical industry in the fields of metabolomics and bioinformatics. Based on this advanced laboratory competence, Zora also develops prognostic and diagnostic biomarkers for disease diagnosis and monitoring of the efficacy and safety of drugs.

Press Office | alfa
Further information:
http://www.zora.fi
http://www.vtt.fi/?lang=en

Further reports about: Biomarker Biosciences metabolomics

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>